Skip to main content

Trace Amine-Associated Receptor 1 (TAAR1) agonists in a chemogenetic/molecular imaging model of increased dopamine synthesis capacity (Ki)


My research plan aims at generating an innovative chemogenetic/positron emission tomography (PET) imaging translational model of striatal dopamine (DA) over-reactivity, the most well-established pathophysiological mechanism underlying schizophrenia. I will use this platform to test the therapeutic efficacy of antipsychotic compounds with a totally new mechanism of action, i.e. targeting the trace amine-associated receptor 1 (TAAR1). Pre-clinical findings will have immediate translation to humans. I envisage a two-fold utility of this platform for the scientific community: 1) development of innovative therapeutic strategies for psychotic disorders; 2) ask fundamental questions about the pathophysiology of schizophrenia.
A substantial share of patients treated with available antipsychotics do not respond and/or experience undesirable side effects. Available antipsychotics do not target the neurobiological mechanisms underlying schizophrenia symptoms, i.e. increased pre-synaptic DA synthesis capacity (Ki) in the striatum. They rather rely on blockade of DA receptors post-synaptically, possibly causing iatrogenic DA super-sensitivity. Therefore, there is a quest for improved therapeutic strategies, addressing DA over-reactivity. A novel target is represented by TAAR1, a G protein-coupled receptor that has been found to crosstalk with the DAergic system. Based on these premises, the objectives of this project are:
-Work package 1. To develop a chemogenetic translational mouse model of increased striatal Ki. We will use [18F]-FDOPA PET imaging to determine if selective manipulation of midbrain neuron firing increases Ki.
-Work package 2. To determine if TAAR1 agonists (TAAR1 toolbox) decrease striatal Ki in the model from WP1. We will ascertain whether TAAR1 is necessary for the effect on Ki, using TAAR1 knock-out (KO) mice.
-Work package 3. To determine whether TAAR1 toolbox modulate Ki in patients with a diagnosis of schizophrenia, applying [18F]-FDOPA PET imaging.

Call for proposal

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF


South Kensington Campus Exhibition Road
SW7 2AZ London
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 212 933,76